On this background, we investigated the expression level of FOXA1 in endometrial cancer in relation to phenotype and established biomarkers including hormone receptor status; and subsequently explore transcriptional alterations related to FOXA1 protein levels in primary and metastatic endometrial carcinoma lesions. This evidence concerns the gene NR4A1 and endometrial cancer.